<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258644</url>
  </required_header>
  <id_info>
    <org_study_id>BFH-CamrelizumabCombo4</org_study_id>
    <nct_id>NCT04258644</nct_id>
  </id_info>
  <brief_title>Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional clinical trial to assess the efficacy and safety of camrelizumab in
      combination with apatinib mesylate, paclitaxel-albumin and S-1 for translational treatment of
      gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>3 years</time_frame>
    <description>proportion of patients for whom radical resection can be achieved</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>3 years</time_frame>
    <description>objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>3 years</time_frame>
    <description>disease free survival (period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year DFS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year disease free survival (rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>progression free survival (period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>overall survival (period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year OS</measure>
    <time_frame>1 year</time_frame>
    <description>1-year overall survival (rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year OS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year overall survival (rate)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab+Apatinib+Paclitaxel-albumin+S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab：D1, 200 mg ivgtt Apatinib Mesylate：D1~21, 250 mg, po qd Paclitaxel-albumin：D1&amp;D8, 100～120 mg/m2 S-1：D1~14, 60mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab+Apatinib+Paclitaxel-albumin+S-1</intervention_name>
    <description>Combination therapy of 4 drugs, 21 days for one cycle.</description>
    <arm_group_label>Camrelizumab+Apatinib+Paclitaxel-albumin+S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age:18～70; expected survival＞3 months

          2. pathologically diagnosed gastric cancer or esophageal-gastric-junction cancer, being
             predominantly adenocarcinoma

          3. no previous treatment of anti-cancer drugs

          4. ECOG score 0~2

          5. CT/MRI/PET-CT diagnosed as unresectable

          6. no disfunction of major organs

          7. lab results satisfy the following criteria:

               -  Hb≥90g/L

               -  WBC≥3.5×109/L

               -  Neutrophil≥1.5×109/L

               -  Plt≥100×109/L

               -  ALT、AST≤2.5 upper limit (≤5 upper limit for patients with liver metastasis)

               -  Tbil≤1.5 upper limit

               -  serum creatinine≤1.5 upper limit

        7.women at child-bearing age must be tested negative within 7 days before inclusion, and
        must be willing to take contraception measures during treatment and within 12 weeks after
        last dose of treatment; men must be sterilized or willing to take contraception measures
        during treatment and within 12 weeks after last dose of treatment 8.willing to join this
        research with hand-signed written Informed consent 9.good compliance for follow-up

        Exclusion Criteria:

          1. patients with positive HER-2 test

          2. with conditions that affect the absorption of oral drugs, such as inability to
             swallow, nausea and vomiting, chronic diarrhea and intestinal obstruction

          3. allergic to carrizumab for injection, apatinib mesylate, paclitaxel for injection
             (albumin binding type) and tS-1 or relevant drug excipients; allergic to any other
             monoclonal antibodies; cannot tolerate radiation toxicity;

          4. with active autoimmune disease or autoimmune disease history, such as interstitial
             pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis,
             nephritis, hyperthyroidism, hypothyroidism (can be included after hormone replacement
             therapy); patients with complete remission of childhood asthma and require no
             intervention can be included, whereas those who need medical intervention with
             bronchodilator cannot be included

          5. with congenital or acquired immune defects, such as human immunodeficiency virus (HIV)
             infection, active hepatitis B (HBV DNA ≥ 500 IU / ml), hepatitis C (HCV antibody
             positive, and HCV-RNA higher than the lower detection limit of the analysis method) or
             combined hepatitis B and hepatitis C co infection

          6. immunosuppressive drugs were used within 14 days before the first use of the study
             drug, excluding nasal spray and inhaled corticosteroids or systemic steroids in
             physiological dose (i.e. no more than 10 mg / day of prednisolone or other
             corticosteroids for equivalent amount);

          7. inoculated live attenuated vaccine within 4 weeks before the first administration or
             during the study period

          8. severe infection (requiring intravenous drip of antibiotics, antifungal or antiviral
             drugs) within 4 weeks before the first administration, or fever&gt; 38.5° C of unknown
             cause during screening / before the first administration

          9. known history of allogeneic organ transplantation or allogeneic hematopoietic stem
             cell transplantation

         10. objective evidence indicating previous or concurrent pulmonary fibrosis, interstitial
             pneumonia, pneumoconiosis, radiation-induced pneumonia, drug-related pneumonia, severe
             impairment of lung function, etc

         11. patients with hypertension that cannot be restored to the normal range (systolic blood
             pressure ≤ 140 mmHg / diastolic blood pressure ≤ 90 mmHg) after treatment with
             antihypertensive drugs for 3 months

         12. patients with uncontrolled clinical symptoms or diseases of the heart, including but
             not limited to congestive heart failure (NYHA grade ＞ II); unstable or severe angina;
             acute myocardial infarction within 6 months; patients with clinically significant
             supraventricular or ventricular arrhythmia requiring clinical intervention; left
             ventricular ejection fraction (LVEF) ＜ 50%

         13. patients at risk of serious bleeding, including but not limited to severe bleeding
             (bleeding &gt; 30 ml within 3 months), hemoptysis (bleeding &gt; 5 ml within 4 weeks), and
             thromboembolism events (within the past 12 months)

         14. with symptoms indicating Grade 2+ peripheral neuropathy

         15. participating in other clinical trials, or participating in any clinical study for
             drugs within previous 4 weeks

         16. other situations that the researchers regard as not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Deng</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongtao Zhang</last_name>
    <phone>8618811792819</phone>
    <phone_ext>8618811792819</phone_ext>
    <email>zhongtao.z@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhongtao Zhang, M.D.</last_name>
      <phone>8618811792819</phone>
      <phone_ext>8618811792819</phone_ext>
      <email>zhongtao.z@139.com</email>
    </contact>
    <investigator>
      <last_name>Kai Pang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhongtao Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

